CA3150316A1 - Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires - Google Patents

Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires Download PDF

Info

Publication number
CA3150316A1
CA3150316A1 CA3150316A CA3150316A CA3150316A1 CA 3150316 A1 CA3150316 A1 CA 3150316A1 CA 3150316 A CA3150316 A CA 3150316A CA 3150316 A CA3150316 A CA 3150316A CA 3150316 A1 CA3150316 A1 CA 3150316A1
Authority
CA
Canada
Prior art keywords
bispecific compound
optionally substituted
cancer
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150316A
Other languages
English (en)
Inventor
Nathanael S. Gray
Jinhua Wang
Fleur Marcia FERGUSON
Jie Jiang
Inchul YOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3150316A1 publication Critical patent/CA3150316A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés bispécifiques (agents de dégradation) qui ciblent l'ERK5 à des fins de dégradation. L'invention concerne également des compositions pharmaceutiques contenant les agents de dégradation et des procédés d'utilisation desdits composés pour traiter le cancer et les maladies inflammatoires.
CA3150316A 2019-09-27 2020-09-24 Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires Pending CA3150316A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907377P 2019-09-27 2019-09-27
US62/907,377 2019-09-27
PCT/US2020/052371 WO2021061894A1 (fr) 2019-09-27 2020-09-24 Agents de dégradation de l'erk5 utilisés comme agents thérapeutiques dans le cancer et les maladies inflammatoires

Publications (1)

Publication Number Publication Date
CA3150316A1 true CA3150316A1 (fr) 2021-04-01

Family

ID=75166154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150316A Pending CA3150316A1 (fr) 2019-09-27 2020-09-24 Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires

Country Status (5)

Country Link
US (1) US20220378919A1 (fr)
EP (1) EP4034132A4 (fr)
AU (1) AU2020356484A1 (fr)
CA (1) CA3150316A1 (fr)
WO (1) WO2021061894A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078350A1 (fr) * 2020-10-14 2022-04-21 Ranok Therapeutics (Hangzhou) Co. Ltd. Méthodes et compositions pour la dégradation ciblée de protéines
WO2023017446A1 (fr) 2021-08-10 2023-02-16 Uppthera, Inc. Nouveau composé induisant la dégradation de plk1
EP4405338A1 (fr) * 2021-09-20 2024-07-31 Dana-Farber Cancer Institute, Inc. Agents de dégradation erk5 et leurs utilisations
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2024162828A1 (fr) * 2023-02-02 2024-08-08 Uppthera, Inc. Nouveau composé induisant la dégradation de plk1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680757A1 (fr) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Pyrimidodiazepines substituees utiles en tant qu'inhibiteurs de plk1
JP5410432B2 (ja) * 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
CA2748181C (fr) * 2009-01-06 2019-07-16 Nathanael S. Gray Composes pyrimido-diazepinone d'echafaudage de kinase et procedes de traitement de troubles
CN107257800B (zh) * 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
WO2017007612A1 (fr) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
JP7273713B2 (ja) * 2017-02-08 2023-05-15 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド ヘテロ二官能性化合物を用いた調整可能な内因性タンパク質分解
EP3911654A4 (fr) * 2020-03-27 2022-05-11 Uppthera Composé induisant une dégradation sélective de plk1

Also Published As

Publication number Publication date
EP4034132A1 (fr) 2022-08-03
EP4034132A4 (fr) 2023-10-11
US20220378919A1 (en) 2022-12-01
WO2021061894A1 (fr) 2021-04-01
AU2020356484A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
AU2019261938B2 (en) Small molecule degraders of polybromo-1 (PBRM1)
AU2019294836B2 (en) Bispecific degraders
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
CA3150316A1 (fr) Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires
US20230158157A1 (en) Potent and selective degraders of alk
EP3813834A1 (fr) Nouveaux modulateurs du crbn
AU2022311961A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
AU2020272861A1 (en) Degraders of fibroblast growth factor receptor 2 (FGFR2)
AU2019346595B2 (en) Macrocyclic inhibitors of ALK, TRKA, TRKB, TRKC and ROS1
EP4405338A1 (fr) Agents de dégradation erk5 et leurs utilisations
EP4132514A1 (fr) Agents de dégradation de l'arginine méthyltransférase 5 (prmt5) et leurs utilisations
WO2022140554A1 (fr) Agents de dégradation à petites molécules de phosphatidylinositol-5-phosphate 4-kinase de type 2 et leurs utilisations